EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual‐Epigenetically Relieving the MYC‐Correlated Immunosuppression via an Advanced Nano‐Radiosensitizer Potentiates Cancer Immuno‐Radiotherapy

Guohao Wang, Jie Yan, Hao Tian, Bei Li, Xinying Yu, Yuzhao Feng, Wenxi Li, Songtao Zhou, Yunlu Dai iD

Advanced Materials · 2024

DOI: 10.1002/adma.202312588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Guohao Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Immunotherapy, Proto-Oncogene Proteins c-myc, Radiation-Sensitizing Agents. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Faculty of Health Sciences, University of Macau, Multi-Year Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cells can upregulate the MYC expression to repair the radiotherapy‐triggered DNA damage, aggravating therapeutic resistance and tumor immunosuppression. Epigenetic treatment targeting the MYC‐transcriptional abnormality may intensively solve this clinical problem. Herein, 5‐Aza (a DNA methyltransferase inhibitor) and ITF‐2357 (a histone deacetylase inhibitor) are engineered into a tungsten‐based nano‐radiosensitizer (PWAI), to suppress MYC rising and awaken robust radiotherapeutic antitumor immunity. Individual 5‐Aza depletes MYC expression but cannot efficiently awaken radiotherapeutic immunity. This drawback can be overcome by the addition of ITF‐2357, which triggers cancer cellular type I interferon (IFN‐I) signaling. Coupling 5‐Aza with ITF‐2357 ensures that PWAI does not evoke the treated model with high MYC‐related immune resistance while amplifying the radiotherapeutic tumor killing, and more importantly promotes the generation of IFN‐I signal‐related proteins involving IFN‐α and IFN‐β. Unlike the radiation treatment alone, PWAI‐triggered immuno‐radiotherapy remarkably enhances antitumor immune responses involving the tumor antigen presentation by dendritic cells, and improves intratumoral recruitment of cytotoxic T lymphocytes and their memory‐phenotype formation in 4T1 tumor‐bearing mice. Downgrading the radiotherapy‐induced MYC overexpression via the dual‐epigenetic reprogramming strategy may elicit a robust immuno‐radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epigenesis, GeneticImmunotherapyProto-Oncogene Proteins c-mycRadiation-Sensitizing AgentsAnimalsHumansMiceCell Line, TumorDendritic CellsImmunosuppression TherapyInterferon Type INanoparticlesNeoplasmsHydroxamic AcidsDNA Modification MethylasesHistone Deacetylase Inhibitors

Stichwörter der Autor:innen

MYCcancer immuno‐radiotherapyepigenetic reprogrammingmetal‐phenolic networksradiosensitizer

Substanzen

Interferon Type IProto-Oncogene Proteins c-mycRadiation-Sensitizing Agentsgivinostat hydrochlorideHydroxamic AcidsDNA Modification MethylasesHistone Deacetylase Inhibitors

Autor:innen und Institutionen

  • Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
  • MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, 999078, China.
  • Xiamen Cell Therapy Research Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China.

ORCID-Profile: Yunlu Dai

Förderung

  • National Natural Science Foundation of China
  • Faculty of Health Sciences, University of Macau
  • Multi-Year Research Grant
  • Science and Technology Development Fund, Macau SAR
  • Medical Development Foundation
  • Ministry of Education Frontiers Science Centre for Precision Oncology, University of Macau

Zitieren

APA

Wang, G., Yan, J., Tian, H., Li, B., Yu, X., Feng, Y., Li, W., Zhou, S., & Dai, Y. (2024). Dual‐Epigenetically Relieving the MYC‐Correlated Immunosuppression via an Advanced Nano‐Radiosensitizer Potentiates Cancer Immuno‐Radiotherapy. Advanced Materials. https://doi.org/10.1002/adma.202312588

Vancouver

Wang G, Yan J, Tian H, Li B, Yu X, Feng Y, et al. Dual‐Epigenetically Relieving the MYC‐Correlated Immunosuppression via an Advanced Nano‐Radiosensitizer Potentiates Cancer Immuno‐Radiotherapy. Advanced Materials. 2024. doi:10.1002/adma.202312588

BibTeX
@article{Wang2024,
  author = {Wang, Guohao and Yan, Jie and Tian, Hao and Li, Bei and Yu, Xinying and Feng, Yuzhao and Li, Wenxi and Zhou, Songtao and Dai, Yunlu},
  title = {Dual‐Epigenetically Relieving the MYC‐Correlated Immunosuppression via an Advanced Nano‐Radiosensitizer Potentiates Cancer Immuno‐Radiotherapy},
  journal = {Advanced Materials},
  year = {2024},
  doi = {10.1002/adma.202312588}
}
Kostenlos starten →